| |
Newsroom /
Health and Fitness
/
Health and Fitness
/
Colorectal Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010
Colorectal Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010
The Global Colorectal Cancer Therapeutics Market was Worth $7.0 billion in 2009, Driven by the Growth in the Patient Volume and Annual Cost of Colorectal Cancer Therapy
Hyderabad,
AP,
India
(prbd.net)
21/10/2010
GlobalData analysis found that, in 2009, the global colorectal cancer therapeutics market was worth $7.0 billion. Between 2001 and 2009, the market grew at a rate of 27.6%. By 2020, the market is expected to be worth $8.8 billion, indicating a Compound Annual Growth Rate (CAGR) of 2.1% between 2009 and 2020.
The global colorectal cancer therapeutics market is very attractive and has primarily been driven by the growth in patient volume and the annual cost of therapy. The patient volume was driven by increased affordability rates and growth in treatment usage patterns such as the diseased population, treatment seeking population, diagnosis population and prescription population. The annual cost of colorectal cancer therapy was driven by the launch of new therapies such as oxaliplatin, capecitabine, bevacizumab and cetuximab. Further, the annual cost of therapy was also driven by the increased adoption of combination therapies such as FOLFOX (5-fluorouracil, leucovorin and oxaliplatin), FOLFIRI (5-fluorouracil, leucovorin and irinotecan), 5FU/LV (5-fluorouracil, leucovorin) and CAPOX (capecitabine and oxaliplatin) in the first-line and second-line treatment of metastatic colorectal cancer patients.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Colorectal-Cancer--Global-Drug-Forecasts-and-Treatment-Analysis-to-2020--Q4-2010&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Bevacizumab, in combination with FOLFOX therapy, became the standard of care for the first-line treatment of metastatic colorectal cancer patients. Similarly, cetuximab in combination with FOLFIRI became one of the most common prescribed treatments for metastatic colorectal cancer patients with the KRAS wildtype.
In 2009, the US was the leading market in the global colorectal cancer therapeutics market with an estimated market share of 54.8%. Japan was the second leading market with an approximate market share of 13.4%, closely followed by France with an approximate market share of 9.6%.
GlobalData, the industry analysis specialist, has released its new report, “Colorectal Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010”. The report is an essential source of information and analysis on the global colorectal cancer therapeutics market. The report provides comprehensive information on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global colorectal cancer therapeutics market. It analyses the treatment usage patterns in the global colorectal cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global colorectal cancer sector. It quantifies the unmet need in the global colorectal cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Colorectal-Cancer--Global-Drug-Forecasts-and-Treatment-Analysis-to-2020--Q4-2010&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.globaldata.com
For more details contact :
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|